Mount Vernon Cancer Centre (MVCC) has been named the highest international participant into a new study into new drug that could prove an effective treatment for advanced renal cell cancer (RCC).
The CABOPOINT Study is a phase two clinical trial looking at a therapy drug called Cabozantinib, which may be used as second line of treatment for RCC.
The study has managed to recruit patients across 50 centres, with MVCC proving the highest recruiter of all sites, with nine RCC patients taking part.
Local consultant medical oncologist and principal investigator in the trial, Dr Anand Sharma, remarked on the importance of the study, saying: “This trial will answer an important question of the best treatment option in second line advanced renal cancer, and is looking at the suitable treatment algorithm, after patients fail on first line immunotherapy combination treatments.
“Mount Vernon Cancer Centre is amongst the top five highest recruiters for renal cancer trials in the country. Our centre offers novel therapies to patients as soon as they are approved by the regulatory authorities or as part of clinical trials.”
The study has now been completed, with patients being followed up by the research team so they can assess the safety of the treatment, patient response and their overall quality of life.
Picture credit NHS East and North Hertfordshire Trust
0 Comments